Guideline Recommendations Support Regular Risk Assessments to Help Guide PAH Treatment Decisions1

Achieving Low-Risk Status Is the Goal of Pulmonary Arterial Hypertension (PAH) Treatment1,2

  • Usually associated with improved outcomes3,4
  • Consider treatment escalation in patients not achieving low-risk status
  • Conduct follow-up risk assessment every 3 to 6 months

Simplified REVEAL Lite 2 Complements REVEAL 2.0 in Clinical Practice3,4

REVEAL 2.0: Refinement of the original REVEAL risk calculator

13 PARAMETERS

  • Treatment-naïve patients: Recommended to be used at baseline, 4- to 6-month, and yearly evaluations
  • Established patients: Recommended to be used at yearly evaluation

REVEAL Lite 2: A simplified and robust calculator that closely approximates REVEAL 2.0 at discriminating risk

6 PARAMETERS

  • Recommended to be used in both treatment-naïve and established patients
  • Recommended to be used in routine clinical practice between full REVEAL 2.0 assessments to monitor trajectory

Developing the REVEAL Lite 2 Risk Calculator

Read about the development and validation of the REVEAL Lite 2 Risk Score Calculator in CHEST

View the Publication

Get the REVEAL 2.0 and REVEAL Lite 2 Risk Calculators

Download the REVEAL 2.0 and REVEAL Lite 2 Tear Pad to gain access to the calculators for use during your next virtual patient visit

Download the Tear Pad

Incorporating Risk Assessment Into Your Organization’s EHR System

The EHR System Build Guides provide step-by-step instructions to help your organization build an automated flowsheet that calculates REVEAL 2.0 and/or REVEAL Lite 2 risk scores within your Epic ® or Cerner® EHR system.

You can also add a clinical decision support (CDS) alert to remind you to perform a risk assessment based on your patient’s age and diagnosis suggesting PAH.

Additionally, there is an optional In Basket message that can be sent to your inbox (for Epic® only). The guides are designed so that you can customize builds and alerts based on the complexity level of your needs.

  • The flowsheet automatically pulls in any applicable structured data fields (eg, blood pressure, lab result [such as BNP level]) that are part of the risk assessment
  • Other PAH measures you assess (eg, 6MWD, FC) are manually populated by clinician assessment
  • Provides an EHR flowsheet to assess and track risk parameters over time
  • Allows you to track trends and pull reports on specific risk parameters for individual or multiple patients
Epic® EHR System Build Guide
Download Epic® EHR System Build Guide
Cerner® EHR System Build Guide
Download Cerner® EHR System Build Guide

Actively monitor your patients’ measures of PAH with the Care4Today® app and Care Portal

Get Started Today

Risk Assessment
Resources

Explore risk assessment resources for you and your patients

Download Resources
6MWD=6-minute walk distance; BNP=brain natriuretic peptide; EHR=electronic health record; FC=Functional Class; REVEAL=Registry to Evaluate Early and Long-term PAH Disease Management.
References: 1. Galiè N, Humbert M, Vachiéry J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46(4):903-975. 2. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018 3. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. CHEST. 2019;156(2):323-337. 4. Benza RL, Kanwar MK, Raina A et al. Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. CHEST. 2021;159(1):337-346. doi:10.1016/j.chest.2020.08.2069